FLAGSTAFF, Ariz., Feb. 11, 2019 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, today announced the retirement of Grover Wickersham, and the addition of Kenneth Siegel to the Board of Directors.
"We are very fortunate and pleased to welcome Mr. Siegel to our Board to fill Mr. Wickersham's seat. Grover's guidance and experience on our Board since 2015 in launching our IPO has provided a foundation for our public company that we are grateful for. We appreciate his service and continued support in searching for and selecting the right leaders for the right time," said Dr. Loretta P. Mayer, Chair, CEO and Co-Founder of SenesTech.
"It is an honor to welcome Ken Siegel to the Board. He is a highly regarded leader in the hospitality industry. His extensive executive experience will be an asset to the company as will his unique perspective and passion for our flagship product. We also thank Grover Wickersham for his years of service to SenesTech. He has made a significant contribution to the company through his guidance and counsel," said Dr. Jamie Bechtel, lead independent Board member of SenesTech.
Ken Siegel has over 25 years of experience as an executive and senior leader of major corporations. Most recently Siegel served as President at Diamond Resorts International Inc. Prior to his tenure at Diamond, Siegel was Chief Administrative Officer and General Counsel of Starwood Hotels & Resorts. Siegel's experience includes all facets of corporate leadership including operations, strategy, finance, and administrative functions. An instrumental member of the Starwood leadership team, Siegel was intimately involved in Starwood's emergence as an industry leader before its acquisition by Marriott International in 2016. Siegel played a pivotal role in Starwood's transition to an asset-light business and was the architect of transactions that drove both top- and bottom-line benefits through industry leading initiatives.
"I am excited to be joining SenesTech as it expands commercialization of its flagship product," said Mr. Siegel. "It's high efficacy coupled with a lighter touch on the environment is a model for creating novel solutions to age old problems. I look forward to working with the management team to help build upon the strong foundation they have created."
Mr. Wichersham retires as a member of the Nomination and Governance Committee. The Nomination and Governance Committee is now comprised of Dr. Jamie Bechtel, Mr. Matthew Szot, Mr. Ken Siegel and Mr. Marc Dumont. Mr. Siegel will also join the commercialization committee.
Dr. Mayer concluded, "The membership of our Board continues to evolve consistent with our place in the growth trajectory of a strong and steady sustainable company. The work performed by our Nominating and Governance committee has been responsive and focused on our growth and timely needs. We are pleased with where we are, who we have become, and most of all with the promising future that lies ahead."
SenesTech is changing the paradigm of pest management by targeting the root cause of the problem: reproduction.
ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.
We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.
Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. Forward looking statements include, but are not limited to, our expectation regarding sales commitments, our expectation regarding the conversion of sales commitments and programs to revenue, our belief that our product is more humane, less harmful to the environment and more effective than traditional methods, and our belief that ContraPest will establish a new paradigm in rodent control without environmental effects of rodenticides. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, email@example.com
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143
SOURCE SenesTech, Inc.